Role of Bacillus sycoccus in treatment of Urinary Tract Infection

Exploring the role of Bacillus sycoccus in the treatment of Urinary Tract Infection through Urinary Tract Infection Symptom Assessment Questionnaire - An uncontrolled experimental study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055272

Enrollment

Registered

2023-07-17

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Bacillus sycoccus: Oral administration of Bacillus sycoccus in either 30 or 200 potency in form of globules size 40. Dosage and Repeatition - bd or tds for seven or fourteen days. Cont

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients giving consent for the study 2. Patient diagnosed with lower UTI on the basis of urine culture. 3. Symptoms are mention in OA Julian and William Boericke 4. Irritating urine (burning) 5. Strong smell 6. Frequent proteinuria 7. Cystitis 8. Tenesmus of bladder 9. When we find out 3 symptoms in these 5 symptoms then we prescribe Bacillus sycoccus in patients of UTI.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with Chronic Kidney Disease, Nephrotic Syndrome 2. Known cases of any other severe systemic disorders and malignancies. 3. Gross developmental defects or structural abnormality of kidney 4. Persons who have a catheter, urinary stent, or nephrostomy tube; recipients of a kidney or other organ transplant; patients on kidney dialysis 5. Pregnant women and lactating mothers will not be included in the study. 6. All complicated cases of UTI.

Design outcomes

Primary

Measure	Time frame
According to the scores obtained pre & post treatment from the UTISA Scoring methodTimepoint: According to the scores obtained pre and post treatment from the UTISA Scoring method at baseline and after three months of treatment	—

Secondary

Measure	Time frame
NOT APPLICABLETimepoint: NOT APPLICABLE	—

Countries

India

Contacts

Public ContactDr Surbhi

Dr MPK Homoeopathic Medical College Hospital and Research Centre

Jyotisharmasky11@gmail.com9785835468

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026